AML

EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene(TM) + IL-2

First Drug Regimen Shown to Prevent AML Relapse TARRYTOWN, N.Y., Dec. 10 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today released new clinical data that demonstrate a durable improvement in leukemia-free survival (LFS) over five years amon...

Low micro-RNA level linked to high gene activity in AML

COLUMBUS, Ohio A new study suggests that a type of acute leukemia may occur in part because abnormally low levels of one small molecule result in the over-activity of genes important to the disease. The research involved patients with acute myeloid leukemia (AML) and a gene mutation called N...

High-Dosage of Epirubicin and Cyclophosphamide may cause AML

Adjuvant chemotherapy with epirubicin and cyclophosphamide for early breast cancer// patients increased the risk of Acute myeloid leukemia or Myelodysplastic syndrome. Recent study published in Journal of clinical oncology reports that early breast cancer patients undergoing chemotherapy with ...

Genome of Leukemia Patient Reveals Common Mutations

...gest they play a role in the development and progression of cancer, they said. The researchers sequenced the genome of a man who was diagnosed with aml at age 38 and had been in remission for more than three years. He was selected for genome sequencing because he had typical clinical and molecular fea...

Comprehensive Look at Rare Leukemia Finds Relatively Few Genetic Changes Launch Disease

...es the need for more detailed look at the complete aml genome MEMPHIS, Tenn., July 27 /PRNewswire...data raise the possibility that the development of aml may require fewer genetic alterations than other c...rs have lots of alterations," he explained. aml accounts for about 20 percent of childhood leukemi...

Toronto researcher's discovery points to a new treatment avenue for acute myeloid leukemia

...odies targeting cancer stem cells significantly reduced the growth of human aml cells that had been transplanted into immune-deficient mice, a laboratory m...Ontario lead the fight against this terrible disease." The research on aml builds on the discovery by Dr. Dick that there is a population of cells wit...

New Drug Could Work Against Leukemia

... Researchers see promise for treatment of aml and other cancers THURSDAY, July 2 (HealthDay News) -- A new targeted therapy shows promise in treating acute myeloid leukemia, a highly t...

Study IDs benefit of donor SCT for adults with acute myeloid leukemia

...w guidelines for treatment of the disease. For all aml patients other than the minority with "good-risk" ... the authors state. The customary treatment for aml involves an initial "induction" phase that uses a ...rgely been based on a chromosome analysis of their aml cells. For...

Donor Stem-Cell Transplant Best For Acute Myeloid Leukemia

...m cells appear to offer the best shot at survival, a new analysis shows. aml is the most common form of acute leukemia, striking about 12,000 adults a y...sk. The researchers found that patients with poor- and intermediate-risk aml who received allogeneic stem cell transplants -- the donor stem cells -- in...

Vion Pharmaceuticals to Present Data on Onrigin(TM)at the ASCO(R) Annual Meeting

...antation-Specific Comorbidity Index (HCT-CI) in Elderly de novo Poor Risk aml Patients Treated with Laromustine" will be presented at the Orange County C... with Infusional Ara-C in Elderly Patients Over Age 60 with Newly Diagnosed aml or High-Grade MDS" will be presented at the Orange County Convention Center...

More>>

AML in Medical Technology

Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients

NEW HAVEN, Conn., Sept. 22 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced today that it had entered into an agreement with the Institut Paoli-Calmettes in Marseille, France to conduct a multi-center Phase I/II clinical trial of laromustine (Cloretazin...

Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy

NEW HAVEN, Conn., Aug. 19 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Pink Sheets: VION) announced today that it had entered into an agreement with the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (the "HOVON") to conduct a clinical trial of laromustine (Cloretazine(...

SuperGen's PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models

DUBLIN, Calif., June 13 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced at the 13th Congress of the European Hema...

Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients

Data Show Encouraging Results for a Potential New Front-Line Treatment Approach in AML CAMBRIDGE, Mass., June 2 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ ) reported preliminary data today from a fully-enrolled pivotal, phase 2 study examining the safety...

SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models

DUBLIN, Calif., April 16 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced as part of a series of presentations at ...

The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce Partnership to Accelerate Development of CPX-351 for AML

WHITE PLAINS, N.Y. and PRINCETON, N.J., Jan. 22 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and Celator Pharmaceuticals, Inc. today announced a partnership to support Phase 2 development of Celator's lead product candidate CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for trea...

Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML

Company to Hold Conference Call at 10:30 A.M. Eastern Time Today NEW HAVEN, Conn., Jan. 8 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION ) today announced that the U.S. Food and Drug Administration (FDA) had lifted the clinical hold on the Phase III trial (Vion Study C...

Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML

CAMBRIDGE, Mass, Dec. 5 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ ) announced today that the company has completed enrollment of a phase 2 clinical trial examining the safety and effectiveness of Clolar(R) (clofarabine) in previously untreated, older adult patients with acute myel...

Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML

NEW HAVEN, Conn., Aug. 15 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION ) today announced that it had accrued a total of 85 patients to the pivotal Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in previously untreated elderly patients with de novo...

Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting

NEW HAVEN, Conn., June 11, 2007 /PRNewswire-FirstCall/ -- Vion Pharmaceuticals, Inc. announced that it presented clinical data in a poster session at the 12th Congress of the European Hematology Association (EHA) Meeting in Vienna, Austria on its lead anticancer agent Cloretazine(R) (VNP40101M) as...

AML in Medical Definition

Hematopathology

...) • Lymphoma ( Hodgkin's disease , NHL ) • LPD • Myeloma ( Multiple myeloma , Extramedullary plasmacytoma ) Myeloid : Myeloid leukemia ( aml , CML ) • MPD Ph- ( Essential thrombocytosis , Polycythemia vera , Myelofibrosis ) • MDS • Neutropenia Red blood cells / anemia / hemo...

Pathology

...) • Lymphoma ( Hodgkin's disease , NHL ) • LPD • Myeloma ( Multiple myeloma , Extramedullary plasmacytoma ) Myeloid : Myeloid leukemia ( aml , CML ) • MPD Ph- ( Essential thrombocytosis , Polycythemia vera , Myelofibrosis ) • MDS • Neutropenia Red blood cells / anemia / hemo...

AML in Medical Dictionary

Leukemia

...or lymphocytic, which denotes the ... Hutchinson Center research related to Acute Myeloid Leukemia (also known as Acute Myelogenous Leukemia ), aml information, and Acute Myeloid Leukemia risk. ... ...

AML in Biological News

Comprehensive look at rare leukemia finds relatively few genetic changes launch disease

...data raise the possibility that the development of aml may require fewer genetic alterations than other c...ancers have lots of alterations," he explained. aml accounts for about 20 percent of childhood leukemi...about 500 U.S. children. About 60 percent of young aml patients become long-term survivors. This study...

CSHL team develops mouse models of leukemia that predict response to chemotherapy

...ude treatment protocols that closely mimic current aml therapy in people, precisely recapitulate genetic ...ss and response to therapy. Most patients with aml receive the same standardized treatment an initia...er have been correlated with clinical outcome. But aml has proved to be genetically too complex, and the ...

Washington University scientists first to sequence genome of cancer patient

...ant to the patient's cancer. Like most cancers, aml - a cancer of blood-forming cells in the bone marr...t we felt that the answers to why this patient had aml had to be embedded in her DNA." To date, scient...on and treatment." An estimated 13,000 cases of aml will be diagnosed in the United States this year, ...

The MDS foundation supports vidaza's recommendation for European approval

...cally over the age of 65. According to the National Institute of Health, in this patient group, the average 5-year survival rate after diagnosis with aml is only approximately four percent. MDS is a primary neoplasm of the bone marrow that is more prevalent than any of the leukemias. MDS affects the f...

The MDS Foundation supports the FDA's decision to expand vidaza label to include survival data

...cally over the age of 65. According to the National Institute of Health, in this patient group, the average 5-year survival rate after diagnosis with aml is only approximately four percent. MDS is a primary neoplasm of the bone marrow that is more prevalent than any of the leukemias. MDS affects the...

Daisies lead scientists down path to new leukemia drug

...nvestigators looked at whether DMAPT could eliminate leukemia in donated human cells, and in mice and dogs. In all cases, DMAPT induced rapid death of aml stem and progenitor cells, without harming healthy blood cells. DMAPT also has shown potential as a treatment for breast and prostate cancer, melan...

JCI table of contents: Aug. 9, 2007

...ukemia (AML). When researchers from Harvard Medical School, Boston, analyzed the equivalent URE in humans they found that a subset of individuals with aml had a genetic mutation known as a SNP that decreased the ability of this region of DNA to enhance PU.1 gene expression. In the study, which appears...

'Tribbles' protein implicated in common and aggressive form of leukemia

...BPá, another protein that is frequently mutated in aml patients. Additionally, expression of the Tribbles protein was elevated in blood samples from aml patients, further suggesting that it contributes t...verall, the findings suggest that Tribbles induces aml by inactivating the C/EBPá protein. The results we...

New strategy rapidly identifies cancer targets

...It did, confirming that the JAK3 mutations play a central role in leukemia," said Gilliland. While Druker said that only a small proportion of aml patients likely carry JAK3 mutations, he says the technique will help find other cancer-causing mutations. The process is highly technical, but it ...

AML in Biological Technology

Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients

Will Resubmit With New Data from Ongoing Studies CAMBRIDGE, Mass., March 19 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ ) today announced the withdrawal of the European application to extend the Evoltra(R) (clofarabine) product label to include the treatment of elderly p...

Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML

NEW HAVEN, Conn., Aug. 15 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION ) today announced that it had accrued a total of 85 patients to the pivotal Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in previously untreated elderly patients with de novo...

Sunesis Reports Financial Results for the Second Quarter 2009

... this year with the FDA to gain concurrence on our aml registration strategy." Recent Highlights ...t voreloxin shows promising safety and efficacy in aml and in platinum-resistant ovarian cancer. These pr... single agent voreloxin in newly diagnosed elderly aml patients who are unlikely to benefit from standard...

Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia

...In the Phase II study, 61 patients with late stage aml who failed to respond or relapsed after two separa...cal outcome analysis of 594 similar second salvage aml patients, who were treated at the MD Anderson Canc...r Giles said: "Patients with refractory / relapsed aml today have no standard therapy as existing therapi...

Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress

...e American Society of Hematology (ASH) meeting in late 2008, included complete remissions (CRs) in 1 of 3 patients with ALL and 10 of 44 patients with aml (9 CRs and 1 CRp - complete remission without full platelet recovery). Some of these remissions occurred at dose levels as low as one-third to one-ha...

Isis and Partners Present New Research at the American Association for Cancer Research 2009 Annual Meeting

...creased survival in preclinical models of acute myeloid leukemia (AML) suggesting that antisense drugs targeting STAT5 may offer a new avenue to treat aml and related blood disorders. "The work presented at this year's AACR demonstrates the broad applicability of antisense technology and adds to ou...

Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results

...EVEAL-1 trial is enrolling newly diagnosed elderly aml patients unlikely to benefit from standard inducti...in combined with cytarabine in relapsed/refractory aml at the 50th Annual Meeting of the American Society...on. Early data show that six of fourteen evaluable aml patients in first relapse enrolled in the Phase 2 ...

Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM)

...sent an important new treatment option for elderly aml patients, many of whom now have no effective thera...ndard remission-induction therapy in patients with aml and myelodysplastic syndromes (MDS); (iii) a Phase... Cancer Society estimates that 13,290 new cases of aml were diagnosed in the U.S. in 2008....

Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin

...ed to advance the development of voreloxin in both aml and ovarian cancer. We believe voreloxin has the ...stant ovarian cancer study and both of our ongoing aml studies are enrolling well, with 45 aml patients enrolled in the fourth quarter of 2008 al...

Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer

...ation of this randomized Phase 2 study in lung cancer follows very shortly after our publication of positive clinical data from our Phase 1/2 study in aml at the recent ASH conference in San Francisco and represents the first of multiple new clinical trials for this innovative therapy that we hope to ann...

More>>